

NPS-1034

Catalog No: tcsc0019643



Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1221713-92-3

Formula:

$C_{31}H_{23}F_2N_5O_3$

Pathway:

Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK

Target:

c-Met/HGFR;TAM Receptor

Purity / Grade:

>98%

Solubility:

DMSO : 34 mg/mL (61.65 mM; Need ultrasonic)

Observed Molecular Weight:

551.54


Product Description

NPS-1034 is a dual inhibitor of **AXL** and **MET** with **IC₅₀**s of 10.3 and 48 nM, respectively.

IC50 & Target: IC50: 10.3 nM (AXL), 48 nM (MET)^[1]

In Vitro: NPS-1034 is a dual inhibitor of AXL and MET with IC₅₀s of 10.3 and 48 nM, respectively. The expression and activity of AXL is significantly increased in HCC827/ER cells, and NPS-1034 treatment effectively inhibits its tyrosine phosphorylation^[1]. NPS-1034 inhibits the viability of the MKN45 and SNU638 cell lines, which highly express the MET gene and p-MET (phosphorylated MET), with IC₅₀ values of 112.7 and 190.3 nmol, respectively. In contrast, NPS-1034 inhibits AGS, KATOIII, NCI-N87, MKN1, MKN28, and MKN74 cell viability with IC₅₀ values ranging from 1 μmol to more than 10 μmol. MET phosphorylation is dramatically decreased after treatment with NPS-1034 in the MKN45 cells, but not in the MKN28 cells. NPS-1034 inhibits hepatocyte growth factor (HGF)-stimulated MET autophosphorylation (Y1234/1235) in the AGS and MKN1 cell lines with IC₅₀ values of [2].

In Vivo: NPS-1034 inhibits tumor proliferation, which highly expresses p-MET. NPS-1034 treatment induces a clear decrease in the vascularization of the tumors. The expression of alpha-smooth muscle actin (α-SMA) is decreased in the tumor sections of mice treated with NPS-1034. NPS-1034-treated mice show virtually no weight loss, indicating that NPS-1034 is generally well tolerated^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!